Xbrane Biopharma AB

As of June 30, 2026, Xbrane Biopharma AB carries a market capitalization of 218.42M, placing it among publicly traded companies globally. Its enterprise value stands at 232.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Xbrane Biopharma AB's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Xbrane Biopharma AB has 20.61M shares outstanding.

As of June 30, 2026, Xbrane Biopharma AB trades at a trailing price-to-earnings ratio of 45.54. The price-to-sales ratio is 47.76, and the price-to-book ratio stands at 0.41.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 232.63M versus a market cap of 218.42M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Xbrane Biopharma AB maintains a current ratio of 3.19, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.82, indicating elevated leverage, while an interest coverage ratio of -4.49 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Xbrane Biopharma AB posted a return on equity (ROE) of 31.42, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 17.72, measuring how efficiently the asset base is converted into earnings. The company generates approximately 2.98M in revenue per employee across its workforce of 38.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.32 indicates how many times Xbrane Biopharma AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Xbrane Biopharma AB recorded 2.32M in income tax expense. The company reported a pretax loss of -63.43M and 118.62M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Xbrane Biopharma AB's stock has declined approximately 15.61% over the past 52 weeks. The 50-day moving average sits at 10.83, while the 200-day moving average is 9.85.

Over the twelve months ended June 30, 2026, Xbrane Biopharma AB generated 113.10M in revenue and converted that into 118.62M in net income, yielding earnings per share of -0.13. EBITDA reached -51.89M, while operating income came in at -51.89M.

As of June 30, 2026, Xbrane Biopharma AB holds 49.50M in cash and equivalents against 63.71M in total debt, resulting in a net debt position of 8.27M. Total book value stands at 538.85M, with working capital of 220.98M providing operational flexibility.

Xbrane Biopharma AB produced -145.94M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -72.41M in capital expenditures, free cash flow totaled -218.35M - equivalent to -0.43 per share.

Over the twelve months ended June 30, 2026, Xbrane Biopharma AB posted a gross margin of 44.93, reflecting its pricing power and cost economics. The operating margin of -45.88 and net profit margin of 104.88 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.69, meaning Xbrane Biopharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Xbrane Biopharma AB's most recent stock split took place on October 17, 2025 with a 125:1 split ratio.

As of June 30, 2026, Xbrane Biopharma AB has an Altman Z-Score of -1.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.